Loading...
XPAR
DIM
Market cap16bUSD
Apr 08, Last price  
164.05EUR
1D
7.29%
1Q
-17.21%
Jan 2017
173.55%
Name

Sartorius Stedim Biotech SA

Chart & Performance

D1W1MN
P/E
91.16
P/S
5.74
EPS
1.80
Div Yield, %
0.42%
Shrs. gr., 5y
0.98%
Rev. gr., 5y
14.05%
Revenues
2.78b
+0.16%
484,301,000521,053,000268,836,000367,996,000401,231,000432,949,000477,300,000543,964,000588,378,000683,524,000884,331,0001,051,611,0001,081,033,0001,212,152,0001,440,570,0001,910,081,0002,886,977,0003,492,700,0002,775,500,0002,780,000,000
Net income
175m
-43.46%
22,026,00029,019,0004,742,00013,104,00029,092,00038,511,00043,190,00056,756,00066,276,00072,472,000117,999,000153,678,000161,088,000208,052,000234,574,000335,932,000414,400,000876,100,000309,700,000175,100,000
CFO
815m
+29.44%
43,852,00051,715,00026,021,00047,226,00091,855,00072,759,00060,593,00048,927,00090,106,000111,312,000142,789,000156,659,000174,689,000227,289,000310,129,000416,879,000695,971,000612,300,000629,700,000815,100,000
Dividend
Apr 02, 20240.69 EUR/sh

Profile

Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, filtration, purification, and fluid management services; single-use and reusable hollow-fiber membrane devices, as well as presterilized assemblies for cell and gene therapy applications; and cell harvesting and various other solutions for intensified bioprocesses. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production. It serves manufacturers of pharmaceuticals, foods, and chemicals, as well as research and development laboratories. The company was founded in 1870 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.
URL
https://www.sartorius.com/en/company/about-sartorius-stedim-biotech-sa
IPO date
Oct 20, 1994
Employees
11,135
Domiciled in
FR
Incorporated in
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,780,000
0.16%
2,775,500
-20.53%
3,492,700
20.98%
Cost of revenue
2,365,900
2,287,700
2,391,800
Unusual Expense (Income)
NOPBT
414,100
487,800
1,100,900
NOPBT Margin
14.90%
17.58%
31.52%
Operating Taxes
40,700
89,000
250,500
Tax Rate
9.83%
18.25%
22.75%
NOPAT
373,400
398,800
850,400
Net income
175,100
-43.46%
309,700
-64.65%
876,100
111.41%
Dividends
(67,100)
(132,700)
(116,100)
Dividend yield
Proceeds from repurchase of equity
1,191,700
1,300
BB yield
Debt
Debt current
64,600
79,100
23,900
Long-term debt
2,950,600
3,717,400
1,222,300
Deferred revenue
Other long-term liabilities
130,600
126,700
225,300
Net debt
2,312,300
3,639,100
1,114,200
Cash flow
Cash from operating activities
815,100
629,700
612,300
CAPEX
(339,800)
(473,600)
(430,600)
Cash from investing activities
(340,000)
(2,722,700)
(957,500)
Cash from financing activities
84,900
1,986,100
220,700
FCF
450,000
(45,700)
182,021
Balance
Cash
688,800
116,600
133,000
Long term investments
14,100
40,800
(1,000)
Excess cash
563,900
18,625
Stockholders' equity
2,599,800
2,673,200
2,514,200
Invested Capital
6,460,100
6,463,275
3,665,500
ROIC
5.78%
7.87%
27.28%
ROCE
5.61%
7.09%
28.64%
EV
Common stock shares outstanding
96,777
92,161
92,163
Price
Market cap
EV
EBITDA
715,800
725,400
1,282,600
EV/EBITDA
Interest
149,600
138,500
18,600
Interest/NOPBT
36.13%
28.39%
1.69%